Evolution of blood biomarker levels following percutaneous atrial septal defect closure in adults

Geenen, Laurie W; Assis, Lucas Uchoa de; Baggen, Vivan J.M.; Eindhoven, Jannet A.; Cuypers, Judith A.A.E.; Boersma, Eric; Roos‐Hesselink, Jolien W.; Bosch, Annemien E. van den

doi:10.1016/j.ijcha.2020.100582

Cited by 5 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emphasizing fibrosis as the source of the disease, the authors found galectin-3 to be predictive of ventricular tachycardia and ventricular fibrillation in this cohort. An interesting report by Geenen et al [ 45 ] assumed that we have a significant decrease of galectin-3 one day post-atrial septal defect closure in adults, suggesting that it could reflect shunt cessation and subsequently volume overload of the right ventricle. Moreover, in 2020, the results delivered by Kowalik et al [ 46 ] showed galectin-3 to be useful in patients with an overloaded right ventricle; however, only in those with congenitally corrected transposition of the great arteries.…”

Section: Discussionmentioning

confidence: 88%

A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations

Smereczyńska-Wierzbicka

Pietrzak

Werner

2022

IJERPH

View full text Add to dashboard Cite

Galectin-3 as a cardiac biomarker has proven to be a significant prognostic tool in adults. However, it has not yet been established in the pediatric population as a biomarker in daily clinical practice. The aim of the study was to summarize the current knowledge on galectin-3 as a biomarker in children with cardiac conditions by reviewing the literature. Bibliographic databases such as PubMed, Web of Science and Embase were searched, and consequently twelve articles met the inclusion criteria. Supplemental handsearching of references delivered one additional source. These prospective studies concerning galectin-3 as a cardiac biomarker present analyses performed in cohorts composed of healthy children and children with cardiovascular diseases. The results, despite being based on small cohort studies, inform that galectin-3 could serve as a potential biomarker in cardiovascular risk stratification in children with heart failure, arrhythmia, Kawasaki disease or in patients undergoing cardiac surgery. The evidence for the usefulness of galectin-3 in the assessment of such pathologies as idiopathic dilated cardiomyopathy, coarctation of the aorta, functionally univentricular heart or tetralogy of Fallot were not completely confirmed. Galectin-3 seems to be a promising biomarker; however, there is a need for further research to establish its use in daily clinical practice.

show abstract

Section: Discussionmentioning

confidence: 88%

A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations

Smereczyńska-Wierzbicka

Pietrzak

Werner

2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Since it is higher in children with ventricular septal defect associated with pulmonary hypertension, serum Gal-3 concentration was suggested to be a promising marker for risk stratification in such children [38]. In a recently published study that included adults with ASD, serum Gal-3 concentration was the only biomarker that decreased in response to ASD closure as an acute effect [8].…”

Section: Resultsmentioning

confidence: 99%

“…Blood-based biomarkers could provide insight into heart remodeling after ASD closure and predict myocardial inflammation and fibrosis [8]. Serum Galectin-3 (Gal-3) is a multifunctional protein (β galactosidase-binding lectin) secreted by cardiac macrophages.…”

Section: Introductionmentioning

confidence: 99%

Modification of Serum Galectin-3 and Reversal of Cardiac Remodeling Following Pediatric Transcatheter Atrial Septal Defect Closure

Shafei¹,

Kotby²,

Ganzoury³

et al. 2022

Congenital Heart Disease

View full text Add to dashboard Cite

Objectives: We aimed to evaluate the effect of percutaneous atrial septal defect (ASD) closure in children using right heart indices and serum galectin-3 (Gal-3), as potential biomarkers of right heart remodeling. Methods: This case-control prospective study included 40 children with ASD and 25 control subjects. An echocardiographic evaluation was performed before the procedure, as well as 24 h, 1 month, and 6 months after intervention. Serum Gal-3 was measured before, and 1 month after the procedure. Results: Serum Gal-3 concentration, right atrial (RA) dimensions, right ventricular (RV) dimensions, indexed RA area, and right index of myocardial performance (RIMP) were significantly increased in children with ASD compared with control subjects while tricuspid annular plane systolic excursion (TAPSE) was significantly decreased. Six months after closure, RA, and RV dimensions significantly decreased and RV function improved (RIMP decreased and TAPSE increased). Gal-3 oncentration significantly decreased 1 month after ASD closure, but it did not reach normal range compared with control subjects. A positive correlation between Gal-3 and age at closure, RA area, RV dimensions, and RIMP was observed. A positive correlation was observed between the decrease in Gal-3 concentration and the decrease in RA area and RV dimensions 1 month after ASD closure. A significant negative correlation was observed between TAPSE and Gal-3 concentration before and after intervention. Conclusions: Percutaneous ASD closure can improve right-sided indices and decrease serum Gal-3 concentration. Gal-3 can be used as a sensitive biomarker of right heart remodeling, with a decrease in Gal-3 concentration suggesting reversal of maladaptive remodeling.

show abstract

“…A decrease in the Gal-3 levels was reported immediately after the percutaneous closure of atrial septal defects in an adult cohort. However, the parameter returned to its baseline levels three months after the aforementioned procedure, irrespective of the cardiac remodeling processes [ 112 ]. On the other hand, Dudnyk et al claimed that, even if children are completely asymptomatic in post-corrective surgery for CHD, their Gal-3 levels are still elevated and are associated with myocardial disfunction, depicted through modified tissue Doppler imaging measurements [ 113 ].…”

Section: Gal-3 As a Predictor Of Complications Associated With Chd Co...mentioning

confidence: 99%

The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature

Făgărășan

Săsăran

Gozar

et al. 2023

IJMS

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is a novel pro-fibrotic biomarker that can predict both right and left cardiac dysfunction caused by various cardiovascular conditions. Its expression seems to be progressively altered with evolving cardiac remodeling processes, even before the onset of heart failure. Hence, Gal-3 has been found to be an individual predictor of acute and chronic heart failure or to serve as part of an integrated biomarker panel that can foresee adverse cardiac outcomes. In congenital heart disease (CHD), Gal-3 correlates with cardiac mortality and complications in both children and adults and is proposed as a therapeutic target in order to reverse the activation of pro-fibrosis pathways that lead to heart failure. Positive associations between serum Gal-3 levels, post-operatory hospitalization rates, complications and ventricular dysfunction have also been reported within studies conducted on patients with CHD who underwent corrective surgery. Thus, this review tried to address the potential utility of Gal-3 in patients with CHD and particularly in those who undergo corrective surgery. The heterogeneity of the literature data and the lack of validation of the results obtained by the current studies on larger cohorts cannot be neglected, though. Further longitudinal research is required to establish how Gal-3 can relate to long-term outcomes in pediatric CHD.

show abstract

Evolution of blood biomarker levels following percutaneous atrial septal defect closure in adults

Cited by 5 publications

References 33 publications

A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations

A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations

Modification of Serum Galectin-3 and Reversal of Cardiac Remodeling Following Pediatric Transcatheter Atrial Septal Defect Closure

The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature

Contact Info

Product

Resources

About